EAM
BOLT icon

Eventide Asset Management’s Bolt Biotherapeutics BOLT Stock Holding History

Eventide Asset Management’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-42,991
Closed -$2.36M – 138
2022
Q1 		$2.36M Sell
42,991
-29,484
-41% -$1.98M 0.04% 134
2021
Q4 		$7.1M Buy
72,475
+45,775
+171% +$8.69M 0.09% 120
2021
Q3 		$6.75M Hold
26,700
– – 0.09% 130
2021
Q2 		$8.26M Buy
26,700
+10,553
+65% +$4.28M 0.11% 123
2021
Q1 		$10.6M Buy
+16,147
New +$10.5M 0.16% 115

Other funds holding BOLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Eventide Asset Management's BOLT Position: Q2 2022 in Review

Eventide Asset Management sold out of Bolt Biotherapeutics (BOLT) in Q2 2022, closing a stake of 42,991 shares — an estimated $2.36M sold.

Eventide Asset Management first reported a position in BOLT in Q1 2021 and held it in 5 quarters. The position peaked at $10.6M in Q1 2021. 61 funds tracked by Wall St. Rank hold BOLT as of Q2 2022.

  • Eventide Asset Management reported no remaining Bolt Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Eventide Asset Management sold 42,991 Bolt Biotherapeutics shares in Q2 2022, an estimated $2.36M.
  • Eventide Asset Management first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 5 quarters.
  • Eventide Asset Management's Bolt Biotherapeutics position peaked at $10.6M in Q1 2021.
  • 61 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2022.

Based on Eventide Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.